The Case for Moving Faster in Depression Care
A new analysis published in Psychiatric Times makes a straightforward but important argument: clinicians treating treatment-resistant depression (TRD) get better results when they measure symptoms consistently, adjust doses without hesitation, and address side effects proactively. The piece argues that too many patients languish in suboptimal treatment phases — partly because providers wait too long to make changes, and partly because symptom tracking is inconsistent or informal.
The article centers on what researchers call measurement-based care (MBC) — a structured approach where validated symptom scales are used at every visit to guide clinical decisions. When combined with a willingness to dose-optimize quickly (rather than waiting weeks to see if a starting dose "works"), the data suggest patients reach remission significantly faster. Side effect management plays a supporting role: unaddressed adverse effects are a leading reason patients abandon otherwise effective treatments before they have a real chance to work.
While the article covers the broader TRD treatment landscape — including antidepressants, augmentation strategies, and newer modalities — its principles apply with particular force to ketamine and esketamine therapy, where dosing flexibility, symptom tracking, and patient support are central to outcomes.
Why This Framework Matters for Ketamine Patients Specifically
Ketamine therapy sits at an interesting intersection within TRD care. It's among the fastest-acting interventions available — often producing measurable antidepressant effects within hours to days — but that speed doesn't eliminate the need for ongoing clinical judgment. If anything, ketamine's rapid mechanism makes the principles described in this article more relevant, not less.
Consider dosing. Standard IV ketamine infusion protocols typically start at 0.5 mg/kg over 40 minutes, but this is a starting point, not a fixed rule. Research and clinical experience both show that some patients respond better at slightly higher or lower doses, or with modified infusion timing. Providers who treat dosing as a fixed protocol rather than an iterative hypothesis are likely leaving outcomes on the table. The same logic applies to esketamine (Spravato): the approved schedule includes flexibility in maintenance dosing frequency, and good clinical management means using that flexibility based on how individual patients are actually responding — not defaulting to the minimum required visits.
Symptom measurement matters here too. One practical challenge with ketamine programs is that some clinics focus heavily on the acute infusion experience without building in structured follow-up to track whether depression is genuinely improving week over week. A patient who feels better immediately after an infusion but isn't being tracked with validated tools between sessions may be missing important signals — including early signs that their response is fading and a schedule adjustment is warranted.
Side effect management is another area where this framework applies directly. Dissociation, transient blood pressure elevation, nausea, and post-infusion fatigue are all manageable — but only if providers are actively asking about them and have clear protocols to respond. Patients who experience poorly managed side effects are more likely to delay or skip sessions, which undermines treatment continuity and, ultimately, outcomes.
Key Takeaway
The quality of TRD care — including ketamine therapy — depends not just on which treatment you receive, but on how actively your provider manages it. Structured symptom tracking, willingness to adjust dosing, and proactive side effect support are the clinical behaviors that separate adequate care from excellent care. When evaluating ketamine providers, ask specifically how they measure your progress and how they decide when to make changes.
Questions Worth Asking Any Ketamine Provider
This research reinforces something that's often underemphasized when people compare ketamine clinics: the clinical process around treatment matters as much as the treatment itself. Two patients can both receive IV ketamine infusions and have meaningfully different outcomes based on how their care is structured and managed between sessions.
Here are practical questions to ask before starting a ketamine program:
- How do you track my symptoms between sessions? Providers using validated tools like the PHQ-9, MADRS, or QIDS are making data-driven decisions — not relying on general impressions or patient self-report alone.
- How do you decide when to adjust my dose or schedule? A thoughtful answer suggests the clinic treats dosing as an iterative clinical process rather than a fixed script applied to every patient.
- What do you do if I experience significant side effects? Clinics with clear protocols for managing dissociation, nausea, or blood pressure changes are better equipped to keep you on track if something uncomfortable arises.
- How do you determine when the initial series is complete, and what comes next? This reveals whether the clinic has a genuine long-term plan for your care or a transactional model focused on completing a package of sessions.
None of this diminishes the importance of ketamine itself — it remains one of the most meaningful advances in TRD treatment in decades. But the Psychiatric Times analysis is a useful reminder that having access to an efficacious treatment and getting the most out of that treatment are two different things. Clinical rigor is what bridges that gap.
The Bigger Picture: A Maturing Field
The broader message here is that TRD care is evolving past its early phase. Initial conversations about ketamine and esketamine centered on whether these treatments work at all — a question now settled enough that the field is shifting focus toward optimization. How do we get more patients to full remission? How do we sustain responses over months and years? How do we identify early who needs a dose adjustment rather than waiting until a response has already deteriorated?
These are the right questions to be asking, and this piece from Psychiatric Times reflects that shift. For patients navigating TRD, that evolution is genuinely good news — it means the clinical community is refining how to use powerful tools more effectively, not just discovering them. The skill and attentiveness of your provider team turns out to be one of the most important variables in your outcome, and knowing what good clinical management looks like puts you in a better position to find it.
Read the original analysis at Psychiatric Times.
Share